Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO-B: Patisiran in Transthyretin Amyloidosis with Cardiomyopathy
2019-001458-24Phase 3Active
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2019
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) and amyloid cardiomyopathy comparing Patisiran with Placebo (2 arms). Primary endpoint: Change from baseline at Month 12 in 6-minute walk test distance. Started Jul 2019; status: active.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2019-001458-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001458-24.